NICE u-turn sees Roche’s Tecentriq backed for lung cancer

06:12 EDT 9 Apr 2018 | PharmaTimes

Following an earlier negative decision NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.

Original Article: NICE u-turn sees Roche’s Tecentriq backed for lung cancer

More From BioPortfolio on "NICE u-turn sees Roche’s Tecentriq backed for lung cancer"